Review: TROP-2 as potential new targe... - Fight Prostate Ca...

Fight Prostate Cancer

3,035 members1,516 posts

Review: TROP-2 as potential new target for prostate cancer therapies

Maxone73 profile image
0 Replies

There are many companies working on TROP-2, mainly as antibody-drug conjugates and even if it's not very widespread in the context of prostate cancer, it is starting to gain traction.

Trop-2 is a promising therapeutic target in prostate cancer, particularly in aggressive subtypes like castration-resistant and neuroendocrine prostate cancer (NEPC), where it drives tumor growth, metastasis, and treatment resistance.

Its overexpression correlates with AR-V7, a marker of resistance to androgen therapies. Antibody-drug conjugates (ADCs), such as Sacituzumab govitecan, selectively deliver cytotoxic agents to Trop-2-positive cells, with efficacy tied to Trop-2 expression levels.

Preclinical studies link Trop-2 to neuroendocrine differentiation and suggest synergy with PARP inhibitors. Challenges include optimizing biomarkers for patient selection and managing ADC-related side effects.

Future research aims to refine combination therapies and validate Trop-2 as a predictive biomarker, offering new hope for advanced prostate cancer.

prostatewarriors.com/2025/0...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Invitro study shows Delta Tocotrienol overcomes Docetaxel resistence in PCa

Necroptosis Induced by Delta-Tocotrienol Overcomes Docetaxel Chemoresistance in Prostate Cancer...
Graham49 profile image

New Target for Neuro Endocrine Prostate Cancer and does your circadian rhythm matter??

Greetings, A new mRNA target for NEPC was discovered in Australia (Oz) for NEPC development. The...
NPfisherman profile image

Warming Up the Cold: A New Hope for Immunotherapy in Prostate Cancer

Ok, Phase 1 data were encouraging, but the sample was small, only 35 patients. But 21% had a PSA...
Maxone73 profile image

Preclinical: Will bacteria save us?? A new amazing tool!

Researchers at UMass Amherst have developed BacID, a bacteria-based cancer therapy that uses...
Maxone73 profile image

Time to impeach for prostate cancer

With finasteride taking trump, we will never see significant research gains. The drug companies...
Challengi profile image